A New Route to Improving Outcomes in Cancer Care: Pharmacist Viewpoints on the Patient-Centric Promise of Subcutaneous Immune Checkpoint Inhibitors (Archive)

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb.


Jaime E. Anderson, PharmD, BCOP, CMQ
Manager, Clinical Pharmacy Services
Department of Clinical Oncology Services
Clinical Pharmacy Specialist
Melanoma and Sarcoma Medical Oncology Departments
University of Texas MD Anderson Cancer Center
Houston, TX

Grace Baek, PharmD, BCOP
Clinical Oncology Pharmacists
UW Medicine/Fred Hutchinson Cancer Center
Seattle, WA

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC
Director of Pharmacy | Minnesota Oncology
St. Paul, MN
Assistant Professor of Pharmacy | Mayo Clinic College of Medicine
Rochester, MN


Dr. Anderson has disclosed that she has no actual or potential conflicts of interest related to this program.

Dr. Baek has disclosed that she has no actual or potential conflicts of interest related to this program.

Dr. Hanna has disclosed that he has received honoraria for non-CME activities Beigene, BMS, Exelixis, and Seagen.

The clinical reviewer, Megan May, PharmD, BCOP has no relevant affiliations or financial relationships with a commercial interest to disclose.

Susanne Batesko, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-24-046-H01-P
Credits: 1.0 hours (0.1 ceu)

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee. This is a free continuing education activity.
Estimated time to complete activity: 60 minutes


June 21, 2024


December 21, 2024


Oncology, managed care and specialty pharmacists

How to Earn Credit

Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


This activity is designed to inform and equip oncology, specialty, and managed care pharmacists with the knowledge, confidence, competence, and practical tools they will need to lead the evidence-based integration of subcutaneous immune checkpoint inhibitors into clinical practice if and when they obtain FDA approval. Patient-centricity will be a central theme of the initiative, with the multifarious role of the pharmacist in making treatment recommendations, educating patients and other clinicians, and provisioning unfettered patient access to novel therapeutic modalities constituting key teachings.


Upon completion of this program, participants should be better able to:

  • Identify the potential of subcutaneous immune checkpoint inhibitors (ICIs) to ameliorate treatment burden associated with IV preparations by improving convenience/satisfaction, promoting adherence, and reducing costs
  • Review the evolving evidence for subcutaneously administered ICIs, including recent readouts, regulatory updates, and ongoing studies
  • Discuss pharmacist considerations regarding implementing subcutaneous ICIs into clinical practice


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Bristol Myers Squibb. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.